Announcements Trials
Browse Landscape

Phase

Phase 4 4Phase 2 3Phase 3 2Phase NA 1Phase 2/3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Vomiting 11Nausea 5Neoplasms 2Breast Neoplasms 2Solid Tumors 1Inflammatory Breast Neoplasms 1Hematologic Neoplasms 1Genital Neoplasms, Female 1Gastrointestinal Neoplasms 1Breast Neoplasms, Male 1

Interventions

Paclitaxel 20Gemcitabine 16Dexamethasone 16Bevacizumab 16Docetaxel 15Oxaliplatin 14Cyclophosphamide 13Carboplatin 12Capecitabine 12Sorafenib 11Fluorouracil 11Leucovorin 10Cisplatin 10pembrolizumab 9Prednisone 9Pemetrexed 9Epoetin Alfa 9venetoclax 8atezolizumab 8Fentanyl 8Drug Therapy 8Doxorubicin 8Rivaroxaban 7Rituximab 7Darbepoetin alfa 7Anastrozole 7Panitumumab 6Ondansetron 6Morphine 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms × Palonosetron × Clear all
NCT03578081 2025-04-06

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Alliance for Clinical Trials in Oncology

Phase 3 Completed
690 enrolled 17 charts
Tumor-Agnostic

Neoplasms

NCT02203253 2016-08-24

Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting

China Medical University, China

Phase 3 Completed
642 enrolled

Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡